DMX-200 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 222 | Primary nephrotic syndrome | 3 |
222. Primary nephrotic syndrome
Clinical trials : 310 / Drugs : 295 - (DrugBank : 117) / Drug target genes : 63 - Drug target pathways : 194
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05183646 (ClinicalTrials.gov) | May 30, 2022 | 29/11/2021 | A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB | A Pivotal Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of DMX-200 in Patients With Focal Segmental Glomerulosclerosis (FSGS) Who Are Receiving an Angiotensin II Receptor Blocker (ARB) | FSGS | Drug: DMX-200;Drug: Placebo | Dimerix Bioscience Pty Ltd | NULL | Recruiting | 18 Years | 80 Years | All | 286 | Phase 3 | United States;Argentina;Australia;Brazil;Denmark;France;Hong Kong;New Zealand;Spain;Taiwan;United Kingdom |
| 2 | EUCTR2021-004174-64-ES (EUCTR) | 26/05/2022 | 22/12/2021 | Efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis | A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving an angiotensin II receptor blocker (ARB) - ACTION3 | Focal segmental glomerulosclerosis MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 21.1;Level: LLT;Classification code 10016832;Term: Focal & segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Repagermanium Product Code: DMX-200 INN or Proposed INN: Repagermanium | Dimerix Bioscience Pty Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 286 | Phase 3 | France;United States;Taiwan;Hong Kong;Argentina;Brazil;Spain;Denmark;Australia;United Kingdom;New Zealand;Korea, Republic of | ||
| 3 | EUCTR2021-004174-64-DK (EUCTR) | 08/03/2022 | 16/12/2021 | Efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis | A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving an angiotensin II receptor blocker (ARB) - ACTION3 | Focal segmental glomerulosclerosis MedDRA version: 21.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 21.1;Level: LLT;Classification code 10016832;Term: Focal & segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Repagermanium Product Code: DMX-200 INN or Proposed INN: Repagermanium | Dimerix Bioscience Pty Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 286 | Phase 3 | France;United States;Taiwan;Hong Kong;Argentina;Spain;Brazil;Australia;Denmark;United Kingdom;New Zealand |